TARSUS PHARMACEUTICALS INC (TARS)

US87650L1035 - Common Stock

54.21  +1.3 (+2.46%)

Full estimates are only available for subscribed users, you can see which data is available below.

Subscribed users also see more surprise data, now it is restricted to 4 quarters.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031
Revenue
YoY % growth
57.03M25.82M
-54.73%
17.447M
-32.43%
177.16M
915.42%
313.52M
76.97%
507.1M
61.74%
722.79M
42.53%
848.78M
17.43%
984.69M
16.01%
1.052B
6.84%
1.244B
18.25%
EBITDA
YoY % growth
-11.85M
55.95%
-62.38M
-426.41%
-142.281M
-128.09%
-129.753M
8.81%
-95.009M
26.78%
40.717M
142.86%
86.873M
113.36%
91.912M
5.80%
92.381M
0.51%
92.84M
0.50%
N/A
EBIT
YoY % growth
-12.16M
54.96%
-62.71M
-415.71%
-143.158M
-128.29%
-130.204M
9.05%
-77.607M
40.40%
77.229M
199.51%
306.21M
296.50%
410.82M
34.16%
530.88M
29.22%
587.16M
10.60%
810.49M
38.04%
Operating Margin
-21.32%-242.87%-820.53%-73.50%-24.75%15.23%42.37%48.40%53.91%55.81%65.15%
EPS
YoY % growth
-0.68
70.66%
-2.55
-275.00%
-4.64
-81.96%
-3.31
28.74%
-1.84
44.24%
1.95
205.76%
-0.45
-123.02%
1.91
525.00%
2.62
37.43%
2.45
-6.61%
N/A

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q4 / 24 Q1 / 25 Q2 / 25 Q3 / 25 Q4 / 25 Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26
EPS
Q2Q % growth
-0.79
39.76%
-0.61
39.27%
-0.61
30.18%
-0.60
0.90%
-0.19
75.91%
0.42
168.18%
0.62
201.27%
0.82
234.98%
1.12
690.13%
Revenue
Q2Q % growth
57.989M
343.48%
65.152M
135.94%
74.211M
81.83%
83.53M
73.59%
90.433M
55.95%
123.62M
89.74%
132.39M
78.40%
146.74M
75.67%
163.79M
81.12%
EBITDA
Q2Q % growth
-33.803M
22.42%
N/AN/AN/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth
-32.518M
26.84%
-31.756M
15.73%
-33.224M
0.23%
-35.124M
-39.59%
-11.494M
64.65%
N/AN/AN/AN/A

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2024
Q2Q % growth
-0.61
52.34%
-0.990.3838.50%
Q2 2024
Q2Q % growth
-0.88
24.79%
-0.940.066.62%
Q1 2024
Q2Q % growth
-1.01
-14.77%
-1.230.2217.81%
Q4 2023
Q2Q % growth
-1.31
-167.35%
-1.390.085.75%
Q3 2023
Q2Q % growth
-1.28
-52.38%
-1.390.118.10%
Q2 2023
Q2Q % growth
-1.17
-387.50%
-1.10-0.07-6.36%
Q1 2023
Q2Q % growth
-0.88
10.20%
-0.960.088.70%
Q4 2022
Q2Q % growth
-0.49
31.94%
-0.700.2130.38%
Q3 2022
Q2Q % growth
-0.84
-10.53%
-0.990.1515.35%
Q2 2022
Q2Q % growth
-0.24
-172.73%
-0.600.3660.15%
Q1 2022
Q2Q % growth
-0.98
-308.51%
-0.94-0.04-4.68%
Q4 2021
Q2Q % growth
-0.72
-5.88%
-0.740.022.98%
Q3 2021
Q2Q % growth
-0.76
79.51%
-0.44-0.32-71.68%
Q2 2021
Q2Q % growth
0.33 -0.490.82167.87%
Q1 2021
Q2Q % growth
0.47 -0.651.12172.00%
Q4 2020
Q2Q % growth
-0.68 -0.67-0.01-1.01%
Q3 2020
Q2Q % growth
-3.71 -0.54-3.17-586.27%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2024
Q2Q % growth
48.118M
2,471.78%
44.306M3.812M8.60%
Q2 2024
Q2Q % growth
40.813M 32.297M8.516M26.37%
Q1 2024
Q2Q % growth
27.614M
1,004.56%
17.805M9.809M55.09%
Q4 2023
Q2Q % growth
13.076M
30.76%
5.778M7.298M126.31%
Q3 2023
Q2Q % growth
1.871M 407.796K1.463M358.81%
Q2 2023
Q2Q % growth

-100.00%
1.795M-1.795M-100.00%
Q1 2023
Q2Q % growth
2.5M
362.96%
3.188M-688K-21.58%
Q4 2022
Q2Q % growth
10M
2,841.18%
10.2M-200K-1.96%
Q3 2022
Q2Q % growth

-100.00%
2.975M-2.975M-100.00%
Q2 2022
Q2Q % growth
15.28M
-30.61%
13.26M2.02M15.23%
Q1 2022
Q2Q % growth
540K
-98.38%
2.244M-1.704M-75.94%
Q4 2021
Q2Q % growth
340K 6.204M-5.864M-94.52%
Q3 2021
Q2Q % growth
1.24M 5.44M-4.2M-77.21%
Q2 2021
Q2Q % growth
22.02M 4.624M17.396M376.21%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS-2.59% 11.89% 14.63% 14.18%
Revenue5.76% 26.51% 6.59% 7.32%